EDNRA and coronary artery disorder: In cases of ET-1-induced oxidative stress, BQ123 (ETA-R blocker) or BQ788 (ETA-R/ETB-R dual blocker) have been shown to attenuate increased superoxide production in the arteries and veins of patients with coronary artery disease [19] and have been linked to a significant increase in the activity of antioxidant defenses, including glutathione, superoxide dismutase (SOD), and catalase [20,21].